Skip to main content
SpringerLink
Log in

Ulkuskrankheit

Klinische Bewertung 2006

Peptic ulcer disease. Clinical evaluation in 2006

  • Schwerpunkt: Dyspepsie, Gastritis, Ulkusleiden
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Behandlung der peptischen Ulkuskrankheit hat durch die Entdeckung ihrer Hauptursache, der Helicobacter-pylori-Infektion, einen grundlegenden Wandel erfahren. Damit hat sich auch die Therapie des Ulkusleidens geändert, sodass nunmehr die Behandlung der chronischen Infektion im Vordergrund steht und die Therapie des peptischen Ulkus im Wesentlichen auf der H.-pylori-Eradikation beruht. Ein aktuelles Problem der Ulkustherapie ergibt sich aus der zunehmenden Resistenzentwicklung von H. pylori gegenüber den Antibiotika der Eradikationstherapie. Zunehmende Bedeutung nimmt die Häufigkeit von Ulzera ein, die durch nichtsteroidale Antirheumatika (NSAR) und Acetylsalicylsäure induziert werden. Durch die optimierte Säuresekretionshemmung mittels Protonenpumpeninhibitoren sind sowohl die Prävention als auch die Heilung der NSAR-Läsionen im Magen und Duodenum möglich geworden.

Abstract

Treatment of peptic ulcer disease has undergone a radical change due to the discovery of its main cause, the Helicobacter pylori infection. The management of the chronic infection is now the primary aim. Treatment of peptic ulcer essentially consists of eradicating H. pylori. A current problem is the resistance developed by H. pylori to the antibiotics used in eradication regimen. Ulcers that are induced by nonsteroidal antirheumatic (NSAR) agents and acetylsalicylic acid are gaining in importance. Optimized inhibition of acid secretion with proton pump inhibitors has made it possible to both prevent and cure ulcers in the stomach and duodenum caused by NSAR agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Sipponen P (1992) Natural history of gastritis and its relationship to peptic ulcer disease. Digestion 51 [Suppl 1]: 70–75

    PubMed  Google Scholar 

  2. McColl KE, el-Omar E (1996) Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. Scand J Gastroenterol [Suppl] 215: 32–37

    PubMed  Google Scholar 

  3. Malfertheiner P, Bode G (1993) Helicobacter pylori and the pathogenesis of duodenal ulcer disease. Eur J Gastroenterol Hepatol 5 [Suppl 1]: 51–58

    Google Scholar 

  4. D’Elios MM, Amedei A, Del Prete G (2003) Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes Infect 5: 723–730

    Article  PubMed  Google Scholar 

  5. McColl KE, el-Omar EM, Gillen D (1997) Alterations in gastric physiology in Helicobacter pylori infection: causes of different diseases or all epiphenomena? Ital J Gastroenterol Hepatol 29: 459–464

    PubMed  Google Scholar 

  6. Lu H, Yamaoka Y, Graham DY (2005) Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 21: 653–659

    Article  PubMed  Google Scholar 

  7. Whittle BJ (2003) Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17: 301–313

    Article  PubMed  Google Scholar 

  8. Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2: 179–191

    Article  PubMed  Google Scholar 

  9. Dogne JM, Hanson J, Supuran C, Pratico D (2006) Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des12: 971–975

    Article  Google Scholar 

  10. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62: 501–509

    Article  PubMed  Google Scholar 

  11. Treiber G, Wex T, Link A et al. (2006) The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Aliment Pharmacol Ther 23: 155–167

    Article  PubMed  Google Scholar 

  12. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (9300): 14–22

    Article  PubMed  Google Scholar 

  13. Malfertheiner P, Kirchner T, Kist M et al.; BYK Advanced Gastric Ulcer Study Group (2003) Helicobacter pylori eradication and gastric ulcer healing – comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 17: 1125–1135

    Article  PubMed  Google Scholar 

  14. Ford AC, Qume M, Moayyedi P et al. (2005) Helicobacter pylori „test and treat“ or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 128: 1838–1844

    Article  PubMed  Google Scholar 

  15. Treiber G, Kist M, Klotz U et al. (2005) Therapie der Helicobacter-pylori-Infektion: Klinische, mikrobiologische und pharmakologische Aspekte. Dtsch Arztebl 102: A1883–1888

    Google Scholar 

  16. Goddard A, Jessa M, Barrett D et al. (1996)Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111: 358–367

    Article  PubMed  Google Scholar 

  17. Vakil N, Lanza F, Schwartz H, Barth J (2004) Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20: 99–107

    Article  PubMed  Google Scholar 

  18. Peitz U, Sulliga M, Wolle K et al. (2002) High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther 16: 315–324

    Article  PubMed  Google Scholar 

  19. Labenz J, Tillenburg B, Peitz U et al. (1996) Ulkusheilung durch Helicobacter pylori Eradikation: genügt eine Woche Therapie? Dtsch Med Wochenschr 121: 3

    PubMed  Google Scholar 

  20. Graham DY, Agrawal NM, Campbell DR et al. (2002) NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162: 169–175

    Article  PubMed  Google Scholar 

  21. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247–1255

    Article  PubMed  Google Scholar 

  22. Lai KC, Chu KM, Hui WM et al. (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118: 1271–1278

    Article  PubMed  Google Scholar 

  23. Scheiman JM, Yeomans ND, Talley NJ et al. (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 Inhibitors. Am J Gastroenterol 22 [Epub ahead of print]

  24. Stupnicki T, Dietrich K, Gonzalez-Carro P et al. (2003) Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 68: 198–208

    Article  PubMed  Google Scholar 

  25. Chan FK, To KF, Wu JC et al. (2002) Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (9300): 9–13

    Article  PubMed  Google Scholar 

  26. Goldstein JL, Johanson JF, Suchower LJ, Brown KA (2005) Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 100: 2650–2657

    Article  PubMed  Google Scholar 

  27. Chan FK (2005) NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 28: 287–300

    Article  PubMed  Google Scholar 

  28. Hawkey C, Talley NJ, Yeomans ND et al.; NASA1 SPACE1 Study Group (2005) Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100: 1028–1036

    Article  PubMed  Google Scholar 

  29. Leontiadis GI, Sharma VK, Howden CW (2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330: 568

    Article  PubMed  Google Scholar 

  30. Chan FK, Ching JY, Hung LC et al. (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Verbindung durch Forschungsprojekte, Vorträge: Altana, Astra Zeneca, Takeda.

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-v.-Guericke Universität, Leipziger Straße 44, 39120, Magdeburg

    P. Malfertheiner & M. Bellutti

Authors
  1. P. Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bellutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Malfertheiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malfertheiner, P., Bellutti, M. Ulkuskrankheit. Internist 47, 588–595 (2006). https://doi.org/10.1007/s00108-006-1630-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-006-1630-y

Schlüsselwörter

Keywords

Search

Navigation